Tyler Lambing

Tx ID, Post things I learn. Views my own

[Tyler Lambing @TylerLambingMD]

Champions league and sonny golden boot 😍

[Tyler Lambing @TylerLambingMD]

FDA now saying you can do 5 doses (a 2nd booster) for COVID in SOT patients, 4 months after first booster https://t.co/k1HYzcqUjt

[Tyler Lambing @TylerLambingMD]

Secondary ppx for nocardia can be considered but no strong evidence. Hesitation given ⬇️ efficacy of low dose TMP/SMX for primary ppx.

[Tyler Lambing @TylerLambingMD]

Hij gaat naar de top, Max is de nummer 1!!!! 🇳🇱🇳🇱🇳🇱🇳🇱🟠🟠🟠🟠

[David van Duin @davidvanduin]

Please RT👍

Come work and learn #TxID with us at UNC. @UNC_ID @anne_lachiewicz @DDHVillanueva @TylerLambingMD @claire_farel @JosephTucker @IDEELlabs @BATLabUNC @joseph_eron @id_bmc @IUIDfellowship @IdBowl

Apply for transplant ID fellowship. Details here:
https://t.co/JYD3UAmJx5

[Formula 1 @F1]

If you're in trouble, he's got your back 👀

We should all try and be a bit more Seb 😇

#BelgianGP 🇧🇪 #F1 @LandoNorris

[Foo Fighters @foofighters]

Yes? 👋 @F1

[Tyler Lambing @TylerLambingMD]

Watching laps 50-51 today at Baku

[Tyler Lambing @TylerLambingMD]

@davidvanduin @DDHVillanueva @Starbucks @UNC_ID @uncglobalhealth @IDfellow_happy @anne_lachiewicz @AndermannTessa @claire_farel @JosephTucker @DDHVillanueva welcome to the alumni club!

[Tyler Lambing @TylerLambingMD]

@CooperIDtweets May also have an effect on cardiac amyloid https://t.co/ecBkUjdVfN

[Tyler Lambing @TylerLambingMD]

Cochrane review: CMV Ig did not reduce risk in SOT when used for CMV ppx. Wide variability in results for various studies though - may be 2/2 to heterogenicity of the precipitants across studies (tx type, immunosuppression) PMID: 17443573

[Tyler Lambing @TylerLambingMD]

CDC recommends for those that are vaccinated and then develop COVID-19 that it should not affect treatment decisions such as monoclonal antibodies https://t.co/Q2fJQ1a94W

[Tyler Lambing @TylerLambingMD]

Happy to be finally fully vaccinated

[Tyler Lambing @TylerLambingMD]

@ShohamTxID Viridans Group Strep Shock Syndrome - was on my broads! https://t.co/xRMnwnzBgY

[Tyler Lambing @TylerLambingMD]

Up to 90% of people receiving MAC treatment may experience treatment-emergent adverse events
https://t.co/h8qDXtdsCE

[Tyler Lambing @TylerLambingMD]

Continuing 2020 IDSA NTM guidelines: for M. abscessus pulm disease, if macrolide sensitive rec 3 drug regimen, for macrolide resistance recommend 4 drug regimen

[Tyler Lambing @TylerLambingMD]

For pulm M. Kansaii tx- fixed 12 months of tx may be enough instead of 12 mo beyond culture conversion. Pooled data from 3 studies only found recurrence rate of ~ 5%.
https://t.co/AuZHL4t5T5

[Tyler Lambing @TylerLambingMD]

Younger tx recipient age associated with increased rates of rejection: thought to be 2/2 to decreased med adherence, T cell changes that come with aging
https://t.co/pLevAjTTQx

[Tyler Lambing @TylerLambingMD]

IDSA currently rec daily tx rather than TIW tx for cavitary MAC as TIW tx has been associated with lower than expected sputum conversion rates

https://t.co/cvu5xpTUsi